CEL-SCI Corp Cash Flow Conversion Efficiency
CEL-SCI Corp cash flow conversion efficiency. Based on the latest financial reports, CEL-SCI Corp (CVM) has a cash flow conversion efficiency ratio of -0.361x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.02 Million) by net assets ($11.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CEL-SCI Corp (1989–2025)
Cash flow conversion efficiency of CEL-SCI Corp from 1989 to 2025. This chart illustrates how CEL-SCI Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CEL-SCI Corp stock price for real-time trading data and today's change.
CEL-SCI Corp Cash Flow Conversion Ratio Explained
CEL-SCI Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CEL-SCI Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CEL-SCI Corp ranked by their cash flow conversion efficiency. Also see CVM market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lithium Plus Minerals Ltd
AU:LPM
|
-0.036x |
|
Nanalysis Scientific Corp
V:NSCI
|
-0.010x |
|
Field Solutions Holdings Ltd
AU:FSG
|
0.158x |
|
Jaycorp Bhd
KLSE:7152
|
-0.009x |
|
CBL International Limited Ordinary Shares
NASDAQ:BANL
|
-0.025x |
|
Merchants Trust PLC
LSE:MRCH
|
0.019x |
|
LOOP INDUSTRIES DL-001
F:3L9
|
0.102x |
|
AIR INDUSTRIES GR.DL-001
F:YH1
|
-0.031x |
Annual Cash Flow Conversion Efficiency for CEL-SCI Corp (1989–2025)
The table below shows the annual cash flow conversion efficiency of CEL-SCI Corp from 1989 to 2025. Review free cash flow generation of CEL-SCI Corp to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $15.96 Million | $-17.12 Billion | -1072.861x | -73284.95% |
| 2024-09-30 | $12.87 Million | $-18.81 Million | -1.462x | +15.44% |
| 2023-09-30 | $13.21 Million | $-22.85 Million | -1.729x | -204.86% |
| 2022-09-30 | $32.16 Million | $-18.24 Million | -0.567x | -70.66% |
| 2021-09-30 | $56.53 Million | $-18.79 Million | -0.332x | +57.09% |
| 2020-09-30 | $19.73 Million | $-15.28 Million | -0.774x | +75.64% |
| 2019-09-30 | $5.13 Million | $-16.32 Million | -3.179x | +99.98% |
| 2018-09-30 | $916.00 | $-13.39 Million | -14617.421x | -353771.50% |
| 2017-09-30 | $-3.34 Million | $-13.79 Million | 4.133x | -82.88% |
| 2016-09-30 | $-956.07K | $-23.08 Million | 24.143x | +429.82% |
| 2015-09-30 | $-5.23 Million | $-23.83 Million | 4.557x | +307.56% |
| 2014-09-30 | $10.44 Million | $-22.93 Million | -2.195x | -8.57% |
| 2013-09-30 | $6.70 Million | $-13.55 Million | -2.022x | -16.58% |
| 2012-09-30 | $7.03 Million | $-12.19 Million | -1.735x | +30.18% |
| 2011-09-30 | $9.08 Million | $-22.56 Million | -2.484x | -440.47% |
| 2010-09-30 | $27.85 Million | $-12.80 Million | -0.460x | +37.61% |
| 2009-09-30 | $8.84 Million | $-6.51 Million | -0.737x | -0.52% |
| 2008-09-30 | $10.84 Million | $-7.94 Million | -0.733x | -119.87% |
| 2007-09-30 | $14.67 Million | $-4.89 Million | -0.333x | -103.58% |
| 2006-09-30 | $-930.60K | $-8.68 Million | 9.323x | +739.38% |
| 2005-09-30 | $2.11 Million | $-3.07 Million | -1.458x | -75.65% |
| 2004-09-30 | $5.30 Million | $-4.40 Million | -0.830x | +59.94% |
| 2003-09-30 | $1.23 Million | $-2.54 Million | -2.072x | +47.99% |
| 2002-09-30 | $1.06 Million | $-4.23 Million | -3.984x | -85.67% |
| 2001-09-30 | $4.00 Million | $-8.59 Million | -2.146x | -226.12% |
| 2000-09-30 | $12.96 Million | $-8.53 Million | -0.658x | +25.84% |
| 1999-09-30 | $7.10 Million | $-6.30 Million | -0.887x | -110.55% |
| 1998-09-30 | $14.00 Million | $-5.90 Million | -0.421x | +58.57% |
| 1997-09-30 | $5.80 Million | $-5.90 Million | -1.017x | -122.64% |
| 1996-09-30 | $11.60 Million | $-5.30 Million | -0.457x | +37.34% |
| 1995-09-30 | $4.80 Million | $-3.50 Million | -0.729x | -22.14% |
| 1994-09-30 | $6.70 Million | $-4.00 Million | -0.597x | -195.79% |
| 1993-09-30 | $10.90 Million | $-2.20 Million | -0.202x | -91.74% |
| 1992-09-30 | $13.30 Million | $-1.40 Million | -0.105x | +89.47% |
| 1991-09-30 | $900.00K | $-900.00K | -1.000x | -- |
| 1990-09-30 | $0.00 | $-700.00K | x | -- |
| 1989-09-30 | $0.00 | $-500.00K | x | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more